Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Celadon Pharmaceuticals PLC ( (GB:CEL) ) just unveiled an announcement.
Celadon Pharmaceuticals Plc has announced ongoing challenges in securing funds from its secured credit facility, with no significant developments since its last update. The company is actively seeking alternative financing options but faces uncertainty in securing additional funding. Despite limited working capital, Celadon continues to receive support from creditors, allowing it to operate into May 2025. However, if funds are not secured promptly, the company may face administration, impacting stakeholders.
More about Celadon Pharmaceuticals PLC
Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company specializing in the development, production, and sale of cannabis-based medicines. The company focuses on improving the quality of life for chronic pain sufferers and exploring cannabis-based treatments for other conditions like autism. Celadon operates a 100,000 sq. ft EU-GMP approved facility in the UK, which includes indoor hydroponic cultivation, GMP extraction, and R&D laboratories. The company holds a Home Office license for commercial supply and owns a clinical trial for cannabis-based treatments for chronic pain. Celadon also has a stake in Kingdom Therapeutics, which is developing cannabinoid medicine for autism.
YTD Price Performance: -56.67%
Average Trading Volume: 258,672
Technical Sentiment Signal: Buy
Current Market Cap: £4.47M
Find detailed analytics on CEL stock on TipRanks’ Stock Analysis page.